GlassScriptPhysician profile
Phillip Saccogna
NPI 1154304632
$6,658.21
in general payments reported to CMS, 2019-2025
21 companies · $1,910 in 2025
The $1,910 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $285 · 2021: $1,202 · 2022: $725 · 2023: $407 · 2024: $1,288 · 2025: $1,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,451 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,450.99 |
| Education | $154.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,904.59 | 2019-2025 | Xpress Loprofile, Scopis Ent, Shaver System |
| Intersect Ent, INC. | $720.16 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $505.49 | 2020-2025 | Dupixent |
| Glaxosmithkline, LLC. | $491.49 | 2021-2025 | Nucala |
| Genzyme Corporation | $473.45 | 2019-2025 | |
| Integra Lifesciences Corporation | $256.87 | 2024-2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Astrazeneca Pharmaceuticals LP | $200.15 | 2025 | Tezspire |
| Spirair, INC. | $191.60 | 2025 | Turbalign, Septalign |
| Acclarent, INC | $184.08 | 2019-2024 | Acclarent Aera, Trudi Nav Cable |
| Neurent Medical Limited | $151.03 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Optinose US, INC. | $119.05 | 2019-2021 | |
| 3nt Medical | $110.05 | 2024 | |
| Aerin Medical INC. | $69.02 | 2022-2025 | |
| Merz North America, INC. | $48.26 | 2019 | |
| Medtronic, INC. | $47.62 | 2022-2024 | Propel |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $46.56 | 2020-2021 | |
| Smith+Nephew, INC. | $38.16 | 2019 | |
| Amgen INC. | $32.36 | 2025 | |
| Paratek Pharmaceuticals, INC. | $27.74 | 2025 | Xhance |
| Eyevance Pharmaceuticals LLC | $20.81 | 2021 | |
| Omeros Corporation | $19.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Saccogna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.